220
Participants
Start Date
July 23, 2018
Primary Completion Date
July 6, 2025
Study Completion Date
July 6, 2025
CCS1477
Capsules, oral
Abiraterone acetate
Abiraterone acetate 500mg tablets plus prednisone/prednisolone
Enzalutamide
Enzalutamide 40mg capsules/tablets
Darolutamide
300mg tablets
Olaparib
150mg tablets
Atezolizumab
840mg/14ml concentrate for solution for infusion vials
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
START CIOCC Hospital Universitario HM, Madrid
Institute Bergonie, Bordeaux
Hôpital Europeen Georges Pompidou, Paris
Institute Gustave Roussy, Villejuif
Dana-Farber Cancer Institute, Boston
Netherlands Cancer Institute (NKI), Amsterdam
Hospital Vall d'Hebron, VHIO, Barcelona
Karolinska Institute, Stockholm
Belfast City Hospital, Belfast
Queen Elizabeth Hospital Cancer Centre, Birmingham
Cambridge University Hospital, Cambridge
Edinburgh Cancer Centre Western General Hospital, Edinburgh
The Beatson West of Scotland Cancer Centre, Glasgow
Leicester Royal Infirmary, Leicester
The Christie Hospital, Manchester
Freeman Hospital, Newcastle
University Hospital Southampton, Southampton
Royal Marsden Hospital, Sutton
Lead Sponsor
CellCentric Ltd.
INDUSTRY